Clinical trials: Chronic Hepatitis c
Hepatitis C Virus
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment…
- Trial name
- NCT02581020
- Where
- 53 sites in Japan
- Volunteers
- 344 people
- Sponsor
- AbbVie
Chronic Hepatitis C Infection, Compensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
The purpose of this study was to evaluate the safety and efficacy of ombitasvir/ paritaprevir/ ritonavir and dasabuvir in adults with genotype 1b chronic hepatitis C virus (HCV) infection and cirrhosis.
- Trial name
- TURQUOISE-III (NCT02219503)
- Testing
- Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir
- Volunteers
- 60 people
- Sponsor
- AbbVie
Chronic Hepatitis C Genotype-1 Relapse
Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients
This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone.
- Trial name
- NCT00983060
- Testing
- NIM811
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
The purpose of this early access program is to provide telaprevir to patients with a specific type of hepatitis C viral infection (termed 'genotype 1') who are expected to benefit from telaprevir-based therapy but who reside in…
- Trial name
- NCT01508286
- Testing
- Telaprevir + peginterferon alfa + ribavirin, peginterferon alfa + ribavirin
- Where
- 128 sites in Australia, Austria and 13 more
- Sponsor
- Janssen-Cilag International NV
Chronic Hepatitis C
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both…
- Trial name
- INSIGHT (NCT01513941)
- Testing
- Telaprevir, Ribavirin, Pegylated-Interferon-alfa-2a
- Where
- 31 sites in Australia, Brazil and 6 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
Hepatitis C, Chronic
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies
- Trial name
- NCT02465203
- Testing
- Previous treatment in DEB025 study
- Where
- 40 sites in United States, Australia and 14 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) versus treatment with peg-IFN and RBV alone in…
- Trial name
- NCT01370642
- Testing
- vaniprevir, Peg-IFN, ribavirin
- Volunteers
- 294 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that…
- Trial name
- NCT00305383
- Testing
- Viramidine, Peginterferon alfa-2b
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis C
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24…
- Trial name
- NCT01359644
- Testing
- PSI-7977, Daclatasvir, Ribavirin
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
The purpose of this study is to compare several Debio 025 (alisporivir)/peg-IFNα2a/ribavirin triple therapies with the current standard of care (SOC) in treatment naïve chronic hepatitis C genotype 1 patients.
- Trial name
- NCT00854802
- Testing
- Debio 025, Peg-IFNα2a, Ribavirin
- Where
- 40 sites in Belgium, France and 5 more
- Volunteers
- 290 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Although injection drug users represent the majority of new and existing cases of infection with hepatitis C virus (HCV), many lack access to treatment because of concerns about adherence, effectiveness, and reinfection.
- Trial name
- NCT00725751
- Testing
- Pegylated interferon alfa-2b (PegIFN-2b), Ribavirin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic…
- Trial name
- NCT02356562
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin
- Volunteers
- 29 people
- Sponsor
- AbbVie
HCV Infection
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to assess the safety, tolerability and effectiveness of ANA598 when administered with pegylated interferon and ribavirin (Standard of Care [SOC]) compared to placebo + SOC.
- Trial name
- NCT00978497
- Testing
- ANA598, Peginterferon, Ribavirin
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
This multi-center, prospective observational study will evaluate the correlation of liver biopsy and transient elastography in liver fibrosis assessment in patients with chronic hepatitis C. Data will be collected for 96 weeks.
- Trial name
- NCT01671046
- Where
- 10 sites in Brazil
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Trial name
- NCT00157534
- Testing
- Celgosivir
- Volunteers
- 43 people
- Sponsor
- BioWest Therapeutics Inc
Chronic Hepatitis C
The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single \& Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects
- Trial name
- HEC110114 (NCT03903081)
- Testing
- HEC110114 tablet
- Where
- China
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C Virus
Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C
The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin
- Trial name
- NCT01629732
- Testing
- Daclatasvir, BMS-986094, Ribavirin
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.
This study will evaluate the efficacy and safety of PEGASYS plus ribavirin in male patients with hemophilia A and chronic hepatitis C. All patients will receive PEGASYS 180 micrograms s.c. weekly plus ribavirin 1000-1200mg p.o.
- Trial name
- NCT00475072
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C
This study evaluated the efficacy and safety of the combination of peginterferon alfa-2a plus ribavirin in treatment-naïve patients with HCV genotype 1b infection, compared with peginterferon alfa-2a monotherapy.
- Trial name
- NCT00144469
- Testing
- peginterferon alfa-2a, rivavirin
- Volunteers
- 300 people
- Sponsor
- Chugai Pharmaceutical
Chronic Hepatitis C
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C
- Trial name
- NCT01726946
- Testing
- VX-135, ribavirin
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Vertex Pharmaceuticals Incorporated